These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36672567)

  • 1. Atrial Fibrillation Risk and Urate-Lowering Therapy in Patients with Gout: A Cohort Study Using a Clinical Database.
    Liu CH; Huang SC; Yin CH; Huang WC; Chen JS; Chen YS; Gan ST; Tzou SJ; Hsu CT; Wu HM; Wang WH
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between urate-lowering therapy initiation and all-cause mortality in patients with type 2 diabetes and asymptomatic hyperuricemia.
    Chen R; Nie S; Zhou S; Su L; Li Y; Zhang X; Luo F; Xu R; Gao Q; Lin Y; Guo Z; Cao L; Xu X;
    Diabetes Metab Syndr; 2024 Jun; 18(6):103043. PubMed ID: 38908114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
    Singh JA; Cleveland JD
    Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Lertnawapan R; Jatuworapruk K
    Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia.
    Hashimoto H; Takeuchi M; Kawakami K
    Clin Rheumatol; 2023 Nov; 42(11):3075-3082. PubMed ID: 37486577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Sawada S; Kajiyama K; Shida H; Kimura R; Nakazato Y; Iguchi T; Oniyama Y; Ishiguro C; Uyama Y
    Clin Transl Sci; 2023 Feb; 16(2):206-215. PubMed ID: 36317407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
    PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.
    Liu D; Zhou B; Li Z; Zhang Z; Dai X; Ji Z; Chen H; Sun Y; Jiang L
    Clin Rheumatol; 2022 Jul; 41(7):2121-2128. PubMed ID: 35229198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.